Contrasting NexImmune (OTCMKTS:NEXI) & Actinium Pharmaceuticals (NYSE:ATNM)

Actinium Pharmaceuticals (NYSE:ATNM) and NexImmune (OTCMKTS:NEXI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Volatility and Risk

Actinium Pharmaceuticals has a beta of -0.3, indicating that its share price is 130% less volatile than the S&P 500. Comparatively, NexImmune has a beta of -2282.12, indicating that its share price is 228,312% less volatile than the S&P 500.

Insider and Institutional Ownership

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 9.9% of NexImmune shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 14.9% of NexImmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for Actinium Pharmaceuticals and NexImmune, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0	0	1	0	3.00
NexImmune	0	0	0	0	0.00

Actinium Pharmaceuticals presently has a consensus price target of $4.00, indicating a potential upside of 207.69%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Actinium Pharmaceuticals is more favorable than NexImmune.

Profitability

This table compares Actinium Pharmaceuticals and NexImmune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
NexImmune	N/A	N/A	N/A

Valuation & Earnings

This table compares Actinium Pharmaceuticals and NexImmune”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90,000.00	450.61	-$48.82 million	($1.10)	-1.18
NexImmune	N/A	N/A	-$32.34 million	($18.29)	N/A

NexImmune has lower revenue, but higher earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than NexImmune, indicating that it is currently the more affordable of the two stocks.

Summary

Actinium Pharmaceuticals beats NexImmune on 7 of the 11 factors compared between the two stocks.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

About NexImmune

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.